ReviewAsian Pacific journal of cancer prevention : APJCP2025
Immunometabolism in the Tumor Microenvironment: Dual Role in Modulating Anti-Tumor Immunity and Tumor Progression.
Review in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer.Scientific reports · 2026Article
- Review
- Immunotherapy role in bladder cancer treatment: a review of literature.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the tumor microenvironment (TME) requires a comprehensive exploration of the interactions between tumor cells and various stromal and immune cells, as these interactions significantly influence tumor growth and treatment response. Immunometabolism, which examines the relationship between immune cell metabolic processes and their behaviour, has become crucial in determining the effectiveness of anti-tumor immune responses. This review explores the intricate relationship between immunometabolism and TME, highlighting how metabolic changes in immune cells can either enhance or impair their capacity to fight cancer. It specifically investigates the metabolic reprogramming of T cells, macrophages, and dendritic cells within the TME and how these alterations affect their anti-tumor roles. The review also examines how tumors utilise metabolic pathways to establish an immunosuppressive environment that fosters tumor growth. Understanding these processes reveals potential therapeutic targets in immunometabolism to improve cancer treatment outcomes. By emphasising the dual role of immunometabolism in both aiding and inhibiting the immune response to cancer, this review underscores the necessity of integrating metabolic strategies into cancer immunotherapy research, which may lead to novel treatments that maximise the immune system's ability to combat cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.